The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...
The weight-loss drug Zepbound (tirzepatide) has just become the first drug approved by the U.S. Food and Drug Administration ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli ...
The Food and Drug Administration (FDA) announced in a statement Tuesday that it has sent warning letters to companies selling ...
If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.